/
FEMY
$3.74-$0.06 (-1.58%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.5M
3M shares
52-week range
$3.50 – $22.20
1% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-159.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $929.1K | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Cost of revenue | $223.7K | $306.5K | $370.4K | $441.9K | $380.1K | $544.9K | $872.4K |
| Gross profit | $705.4K | $731.4K | $809.3K | $764.3K | $691.9K | $1.1M | $1.4M |
| Gross margin | 75.9% | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| R&D | $6.9M | $4.1M | $4.1M | $5.8M | $7.2M | $8.2M | $7.6M |
| Operating income | −$11.6M | −$6.9M | −$8.3M | −$11.6M | −$14.5M | −$17.8M | −$17.6M |
| EBITDA | −$10.2M | −$5.8M | −$6.6M | −$10.5M | −$13.2M | −$16.3M | −$15.9M |
| Net income | −$11.3M | −$6.9M | −$7.5M | −$11.4M | −$14.2M | −$18.8M | −$18.6M |
| Net margin | -1213.3% | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
| EPS (diluted) | -19.20 | -11.80 | -12.80 | -19.40 | -18.60 | -16.80 | -9.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-4.33 | $-5.42–$-3.67 | 2 |
| 2027 | $10M | $-5.27 | $-5.63–$-4.90 | 2 |
| 2028 | $22M | $-4.07 | $-5.53–$-2.86 | 3 |
| 2029 | $52M | $0.67 | $0.57–$0.83 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Femasys Inc. Common Stock
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
www.femasys.com- Employees
- 54
- IPO / List date
- Jun 18, 2021
- HQ
- SUWANEE, GA
Held by traders on TradeandTell
No one on the platform currently holds FEMY.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in FEMY as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-08 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded FEMY yet.
